Paolo A. Ascierto/LinkedIn
Jul 11, 2025, 17:32
Paolo Ascierto: Strategic Innovation in Oncology – Immunotherapy Before Surgery
Paolo Ascierto, Director of Department Melanoma at Cancer Immunotherapy and Development Therapeutics, shared a post on LinkedIn:
“Strategic Innovation in Oncology: Immunotherapy Before Surgery
Recent research highlights a major shift in approach — delivering immunotherapy before surgery is showing promising results across several malignancies, including melanoma; lung, colorectal, and triple-negative breast cancer.
This neoadjuvant strategy is associated with fewer relapses, stronger treatment responses, and renewed hope for many patients. A clinical innovation translating into measurable patient benefit.”
More posts featuring Paolo Ascierto.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 11, 2025, 18:04
Jul 11, 2025, 17:32
Jul 11, 2025, 17:27
Jul 11, 2025, 17:17
Jul 11, 2025, 16:54